NK-92/5.28.z
Phase 1Biologic
NK-92/5.28.z is one of 54 biologic programs targeting Glioblastoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
160 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Antabuse
TevaPhase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NK-92/5.28.z. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details